Company Description
Kazia Therapeutics Limited operates as a biotechnology company, develops anti-cancer drugs.
Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/AKT/mTOR pathway, which is developed as a potential therapy for glioblastoma, diffuse intrinsic pontine glioma/advanced solid tumors, atypical teratoid rhabdoid tumor, brain metastases, triple negative breast cancer, and primary central nervous system lymphoma.
It is also developing EVT801, a small molecule targeted therapeutic vascular endothelial growth factor receptor 3 inhibitor.
The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017.
The company was incorporated in 1994 and is based in Sydney, Australia.
| Country | Australia |
| Founded | 1994 |
| IPO Date | Jan 6, 1999 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 9 |
| CEO | Dr. John Edwin Friend II, M.D. |
Contact Details
Address: 120 Broadway, 32nd Floor New York, New York 10271 United States | |
| Phone | 212 238-3128 |
| Website | kaziatherapeutics.com |
Stock Details
| Ticker Symbol | KZIA |
| Exchange | NASDAQ |
| Fiscal Year | July - June |
| Reporting Currency | USD |
| CIK Code | 0001055886 |
| CUSIP Number | 48669G105 |
| ISIN Number | US48669G1058 |
| SIC Code | 8880 |
Key Executives
| Name | Position |
|---|---|
| Dr. John Edwin Friend II, M.D. | Chief Executive Officer, MD and Director |
| Gabrielle Heaton BBUS (ACC), CPA | Principal Accounting Officer, Vice President of Finance and Administration and Principal Financial Officer |
| Anna Sandham | Company Secretary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 21, 2017 | 424B3 | Prospectus |
| Nov 17, 2017 | 424B3 | Prospectus |
| Jul 11, 2017 | 424B3 | Prospectus |
| Jun 6, 2016 | F-6 POS | Post-effective amendments for immediately effective filing |